Of note, the administration of selumetinib, a MAP kinase (MEK) 1/2 inhibitor which was revealed to be helpful to treat NF1-associated tumors such as plexiform neurofibromas and optic way gliomas, has been recently associated with revascularization failure in NF1-related MMS [29]. The gene discussed is MAP2K1; the disease is plexiform neurofibroma.